TREMFYA® (guselkumab) reimbursed for the treatment of moderately to severely active Crohn’s disease and ulcerative colitis for use in Ireland

Johnson & Johnson (JNJ) reported positive results for its Javelin catheter, meeting both primary goals in a pivotal study. Impella heart pump data showed lower death rates than a previous negative study. Javelin is still under FDA review, and Impella's recovery depends on future trials. JNJ's cardiovascular unit saw a sales decline, with Impella contributing 1.6% of total revenue. Analysts project a ~25% total return for JNJ stock.

Johnson & Johnson (J&J) presented data at a symposium showing lower mortality rates in high-risk PCI patients using Impella heart pumps compared to the CHIP-BCIS3 trial. Three analyses, involving 1,379 patients, reported 30-day mortality rates of 6.1% and 4.7%, and 90-day rates of 6.5%. J&J's heart recovery chief medical officer highlighted the importance of device usage and patient selection. The company continues studying Impella, with PROTECT IV trial results expected in 2027.

Johnson & Johnson (JNJ) reported that its Shockwave Javelin coronary catheter met primary endpoints in the FORWARD CAD study, with 93.6% successful lesion crossing and 93.4% safety. The study involved 158 patients. Separately, J&J shared favorable Impella data from three analyses, showing low mortality rates. JNJ closed at $273.20, down 0.73%.

A substudy of the phase 3 PROTEUS trial, presented at ESMO Congress 2026, showed that perioperative apalutamide plus ADT reduced recurrence or death risk by 62% in high-risk prostate cancer patients. The study, supported by Johnson & Johnson, met primary endpoints, including event-free survival and metastasis-free survival. Lead author Alberto Briganti suggested the treatment could become a standard option for eligible patients.

Johnson & Johnson reported 94% success in a 30-day trial of its Shockwave Javelin catheter, designed for treating hard-to-reach narrowed coronary arteries. The FORWARD CAD study evaluated the device's effectiveness. According to the company, the results are positive. This news may impact investors' perception of JNJ's medical device segment.

Johnson & Johnson presented positive clinical data on Impella heart pumps at TCT 2026, showing lower mortality rates in HRPCI patients. The data, from 1,379 patients, contrasts with recent CHIP-BCIS3 study results. The findings highlight real-world outcomes in U.S. and European hospitals.